Gene expression profiling

Bruker to Acquire the NanoString Business in an Asset Deal

Retrieved on: 
Monday, April 22, 2024
Research, Finance, Genetics, Banking, Professional Services, Biotechnology, Health, Other Science, Science, Goldman Sachs, Sale, Corporation, BRKR, NanoString Technologies, Gene expression profiling, Hand, AlixPartners, Willkie Farr & Gallagher, Acquisition, EPS, Morgan, Lewis & Bockius, Growth, Fine chemical

Under the asset purchase agreement, Bruker expects to acquire substantially all of the assets and rights associated with NanoString’s business, including the nCounter®, GeoMx®, CosMx™ and AtoMx™ product lines, for approximately $392.6 million in cash, and the assumption of certain liabilities.

Key Points: 
  • Under the asset purchase agreement, Bruker expects to acquire substantially all of the assets and rights associated with NanoString’s business, including the nCounter®, GeoMx®, CosMx™ and AtoMx™ product lines, for approximately $392.6 million in cash, and the assumption of certain liabilities.
  • NanoString is a provider of life science tools for discovery and translational research with leading solutions for spatial transcriptomics and gene expression analysis.
  • Following the closing, the NanoString business will become part of the Bruker Spatial Biology business.
  • By 2026, Bruker expects the NanoString business to have rebounded and to be near break-even with resumed revenue growth and margin improvements, also taking advantage of deal synergies, as Bruker is not acquiring NanoString’s public company overhead in this asset deal.

Lexogen launches end-to-end solutions for FFPE Transcriptomics

Retrieved on: 
Wednesday, April 10, 2024
Cancer, Drug design, Paraffin, Transcriptome, Small RNA, Tissue, Gene expression profiling, RNA, Research, Carcinogenesis, Illumina, Data analysis, Neoplasm, Biomarker, RNA-Seq, A-DNA, Vaccine

Drawing from years of experience with transcriptome sequencing from FFPE samples, Lexogen has developed new solutions and carefully optimized established technologies to provide convenient workflows from FFPE sample extraction to data analysis.

Key Points: 
  • Drawing from years of experience with transcriptome sequencing from FFPE samples, Lexogen has developed new solutions and carefully optimized established technologies to provide convenient workflows from FFPE sample extraction to data analysis.
  • Lexogen's FFPE Transcriptomics line includes the SPLIT One-Step FFPE RNA Extraction Kit, QuantSeq FFPE 3' mRNA-Seq Library Prep Kit for gene expression profiling, and CORALL FFPE Whole Transcriptome RNA-Seq with a seamlessly integrated gDNA removal step for whole transcriptome RNA-Seq.
  • The SPLIT One-Step FFPE RNA Extraction Kit allows easy and effective extraction of RNA from FFPE samples in less than 2 hours.
  • QuantSeq FFPE and CORALL FFPE are compatible with SPLIT One-Step FFPE RNA Extraction, include purification solutions and Unique Dual Indices, and come with complimentary data analysis on Lexogen's Kangooroo data analysis platform.

Lexogen launches end-to-end solutions for FFPE Transcriptomics

Retrieved on: 
Wednesday, April 10, 2024
Cancer, Drug design, Paraffin, Transcriptome, Small RNA, Tissue, Gene expression profiling, RNA, Research, Carcinogenesis, Illumina, Data analysis, Neoplasm, Biomarker, RNA-Seq, A-DNA, Vaccine

Drawing from years of experience with transcriptome sequencing from FFPE samples, Lexogen has developed new solutions and carefully optimized established technologies to provide convenient workflows from FFPE sample extraction to data analysis.

Key Points: 
  • Drawing from years of experience with transcriptome sequencing from FFPE samples, Lexogen has developed new solutions and carefully optimized established technologies to provide convenient workflows from FFPE sample extraction to data analysis.
  • Lexogen's FFPE Transcriptomics line includes the SPLIT One-Step FFPE RNA Extraction Kit, QuantSeq FFPE 3' mRNA-Seq Library Prep Kit for gene expression profiling, and CORALL FFPE Whole Transcriptome RNA-Seq with a seamlessly integrated gDNA removal step for whole transcriptome RNA-Seq.
  • The SPLIT One-Step FFPE RNA Extraction Kit allows easy and effective extraction of RNA from FFPE samples in less than 2 hours.
  • QuantSeq FFPE and CORALL FFPE are compatible with SPLIT One-Step FFPE RNA Extraction, include purification solutions and Unique Dual Indices, and come with complimentary data analysis on Lexogen's Kangooroo data analysis platform.

Agendia Presents Data at Miami Breast 2024 Demonstrating MammaPrint® + BluePrint®’s Ability to Further Stratify Tumor Categories in Hormone-Positive Breast Cancer, Highlighting Response to Different Chemotherapy Regimens

Retrieved on: 
Friday, March 8, 2024
Research, Genetics, Other Health, Biotechnology, General Health, Pharmaceutical, Health, Science, Oncology, Other Science, Gene expression profiling, Breast cancer, Neoplasm, Taxane, Woman, Transcriptome, MD, MBCC, Cyclophosphamide, Anthracycline, PCR, MammaPrint, Risk, Conference, Symantec Endpoint Protection, AC-T, Patient, MP, Diagnosis, Triple-negative breast cancer, Blueprint, TC, Medical imaging

The first poster, titled MammaPrint® and BluePrint® predict anthracycline chemosensitivity in patients with HR+HER2-early-stage breast cancer enrolled in FLEX, (Audeh, W., et al.

Key Points: 
  • The first poster, titled MammaPrint® and BluePrint® predict anthracycline chemosensitivity in patients with HR+HER2-early-stage breast cancer enrolled in FLEX, (Audeh, W., et al.
  • ), investigates the associations between MammaPrint and BluePrint classifications, therapy regimen, and the likelihood of achieving a pathologic Complete Response (pCR).
  • The second poster, titled Prediction of chemotherapy benefit by MammaPrint® in patients with HR+HER2-early-stage breast cancer from real-world evidence studies (Audeh, W., et al.
  • Taken together, these findings indicate the utility of MammaPrint to predict neoadjuvant and adjuvant chemotherapy benefit in this patient population.

Asep Medical's Sepsis Diagnostic Technology Can Provide Improved Odds for Pediatric Appendicitis

Retrieved on: 
Tuesday, February 27, 2024
Asep, Incidence, Sepsis, UBC, Medical director, American Medical Association, JAMA, Abdominal pain, Biomarker, Gene expression, Appendectomy, Patent, Appendicitis, Patient, Journal, Data analysis, Pediatrics, Diagnosis, Mortality, Gene expression profiling, Vaccine

VANCOUVER, BC, Feb. 27, 2024 /PRNewswire/ - Asep Medical Holdings Inc. ("Asep Inc." or the "Company") (CSE: ASEP) (OTCQB: SEPSF) (FSE: JJ8) is pleased to announce that its proprietary gene expression signature for sepsis can provide an improved assessment of the severity of appendicitis in children.

Key Points: 
  • VANCOUVER, BC, Feb. 27, 2024 /PRNewswire/ - Asep Medical Holdings Inc. ("Asep Inc." or the "Company") (CSE: ASEP) (OTCQB: SEPSF) (FSE: JJ8) is pleased to announce that its proprietary gene expression signature for sepsis can provide an improved assessment of the severity of appendicitis in children.
  • The study found that the "diagnostic study of 71 patients with pediatric appendicitis using systems immunology methods revealed a mechanistic understanding of severe disease, indicating immune dysregulation similar to that observed in sepsis.
  • The study concluded that early diagnostics and management strategies for pediatric PA should be informed by underlying immune dysregulation and similarities to sepsis.
  • Based on the new potential benefits of this ER technology, we look forward to improving outcomes for children presenting with abdominal pain in the ER."

Vizgen Kicks Off AGBT with Enhanced MERFISH Chemistry Updates and 2024 Product Roadmap Highlights

Retrieved on: 
Monday, February 5, 2024
Neurology, Health, Genetics, Science, Research, Partnership, RNA, Sunset Terrace/Montclair, Houston, Data management, Glass, Mass meeting, Gene, Brain, Gene expression profiling, BioRxiv, Biology, Software

Vizgen , Inc., the life science company dedicated to improving human health by visualizing single-cell spatial genomics information, has unveiled enhanced MERFISH chemistry along with its 2024 product roadmap.

Key Points: 
  • Vizgen , Inc., the life science company dedicated to improving human health by visualizing single-cell spatial genomics information, has unveiled enhanced MERFISH chemistry along with its 2024 product roadmap.
  • In addition to the announcement of these product developments, Vizgen will be presenting three posters at the Advances in Genome Biology and Technology (AGBT) 2024 General Meeting, in Orlando, Florida, this week.
  • The enhanced MERFISH chemistry will extend the best-in-class sensitivity of MERFISH to degraded RNA samples, including archival FFPE samples, enabling translational research.
  • Data demonstrating this superior detection capacity is expected to be released in the coming months, with plans to make the enhanced MERFISH chemistry available to users in the summer of 2024.

Agendia Announces First Patient Enrolled in DEBRA Trial Using MammaPrint®

Retrieved on: 
Thursday, February 1, 2024
Surgery, FDA, Genetics, Clinical Trials, Health Technology, Biotechnology, Radiology, Health, Oncology, DEBRA, Breast cancer, Trial of the century, Radiation, Patient, Recurrence, Gene expression profiling, Manager, Phase, Risk, Biology, Woman, Medical imaging

Agendia®, Inc. , announced today that the first patient to use MammaPrint® as an enrollment biomarker for the DEBRA Trial is to be enrolled.

Key Points: 
  • Agendia®, Inc. , announced today that the first patient to use MammaPrint® as an enrollment biomarker for the DEBRA Trial is to be enrolled.
  • The Phase III NRG Oncology De-Escalation of Breast Radiation (DEBRA) Trial ( NCT04852887 ) is a clinical study looking at safely reducing the use of breast radiation after lumpectomy for people with low-risk, early-stage breast cancer.
  • “With the first patient of this study being enrolled using MammaPrint, we look forward to participating in the development of a new path towards more precise, proactive treatment planning for early-stage breast cancer.”
    To learn more about the DEBRA Trial and enrollment criteria, visit www.nrgoncology.org/DEBRA-Trial .
  • For more information about Agendia, visit www.agendia.com and follow Agendia on Facebook , Twitter , YouTube , and LinkedIn .

Nucleic Acid Isolation and Purification (Genomic DNA, Plasmid DNA, mRNA) Market Research - Global Forecast to 2028 - ResearchAndMarkets.com

Retrieved on: 
Wednesday, January 3, 2024
Other Science, Science, RNA, Kits, Drug discovery, Biotechnology, Agriculture, Gene expression profiling, Messenger, Research, DNA, Region, MicroRNA, Personalized medicine, USD, Genomics, ChromeOS, Diagnosis, Growth, Patient, NAIP, Automation, Vaccine

In 2022, the kits segment accounted for the largest share of the global nucleic acid isolation and purification market.

Key Points: 
  • In 2022, the kits segment accounted for the largest share of the global nucleic acid isolation and purification market.
  • In 2022, the kits segment accounted for the largest share of the global nucleic acid isolation and purification market.
  • Based on type, the global nucleic acid isolation and purification market is segmented into plasmid DNA, total RNA, circulating nucleic acid, genomic DNA, messenger RNA, microRNA, and other nucleic acid isolation and purification types.
  • In 2022, the plasmid DNA isolation and purification segment dominated the global nucleic acid isolation and purification market.

Almaden Genomics’ g.nome™ Further Enhances Single-Cell Analysis

Retrieved on: 
Wednesday, December 13, 2023
Technology, Genetics, Health Technology, Professional Services, Software, Stem Cells, Biotechnology, Data Analytics, Health, Data Management, Beth Singler, HTML, RNA-Seq, QC, Genomics, Gene expression, UMAP, Single-cell analysis, Cell, Gene expression profiling

Almaden Genomics has incorporated an end-to-end solution into g.nome™ to process, analyze, and visualize single-cell RNAseq data.

Key Points: 
  • Almaden Genomics has incorporated an end-to-end solution into g.nome™ to process, analyze, and visualize single-cell RNAseq data.
  • A cloud-native platform designed for high-throughput sequencing data analysis, g.nome now includes features for alignment and quantification of gene expression per cell, Seurat clustering analysis, reference-based cell-type annotation, and built-in parallelization.
  • The g.nome platform also provides a powerful, yet flexible system for single cell analysis with a workflow builder, quick and easy plug-n-play workflows, and interactive visualizations.
  • Single-cell analysis was added to g.nome earlier this year, enabling understanding of cellular diversity and disease mechanisms on a much more granular level.

Intensity Therapeutics Presents Positive INT230-6 Data in Patients with Early-Stage Breast Cancer in a Podium Poster Spotlight Discussion at the 2023 SABCS

Retrieved on: 
Friday, December 8, 2023
Woman, Safety, Therapy, Ottawa Hospital Research Institute, Intensity, Podium, Breast cancer, Fatigue, Patient, Gene expression profiling, Necrosis, The Ottawa Hospital, T helper cell, Immunotherapy, Breast, CD4, Gene expression, Biomarker, Mastectomy, MD, Nausea, Diagnosis, Cancer, University, Downregulation and upregulation, Neoplasm, News, Publication, Injection, NK, Vaccine, Medical imaging

"A large unmet need in the treatment of breast cancer is that the majority of breast cancers are immune quiescent; resulting in minimal response to immunotherapies.

Key Points: 
  • "A large unmet need in the treatment of breast cancer is that the majority of breast cancers are immune quiescent; resulting in minimal response to immunotherapies.
  • A functional pathway enrichment analysis was conducted and confirmed positive changes in T-cell activation, lymphocyte activation and inflammatory response.
  • Over 95% of treatment-emergent adverse events (TEAEs) were low grade 1 or 2 primarily localized pain, fatigue, and nausea.
  • We see the potential opportunity for our technology and drug products in both the metastatic and presurgical settings for many types of cancers."